Company intelligence / Profile preview

Atombeat

Ownership: Private
Development stage: Other

Overview

Atombeat provides validated AI and physics-based computational platforms for drug discovery, enabling rapid hit identification and lead optimization. Their technologies have been benchmarked against industry standards (e.g., AlphaFold 3) and are used in collaborations with top pharmaceutical and biotech companies worldwide. They have demonstrated success in designing high-quality cyclic peptides targeting difficult proteins such as c‑Myc and β-catenin.

Modalities: Small moleculePeptidesMacrocyclic peptidesNovel conjugates
Industry: Drug Discovery Services

Partnerships

Top pharmaceutical and biotech companies worldwide—specific names are not disclosed but successful collaborations are highlighted.Integration with NVIDIA BioNeMo for Uni-Dock v1.1.

Beyond the preview

Go deeper on Atombeat.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atombeat.

Explore the full profile